iifl-logo

Strides Pharma Science Ltd EGM

707.6
(5.68%)
Apr 3, 2025|10:54:54 AM

Strides Pharma CORPORATE ACTIONS

03/04/2024calendar-icon
03/04/2025calendar-icon
PurposeAnnouncement DateMeeting Date
EGM8 Aug 202410 Sep 2024
COM 10/09/2024 Outcome of NCLT Convened meeting - Approval from Equity shareholders and Secured Creditors for creation of OneSource - Indias first Specialty Pharma CDMO (As Per BSE Announcement dated on 11.09.2024)

Strides Pharma: Related News

Strides Pharma Q3 Profit at ₹90 Crore, Revenue Up 15%
31 Jan 2025|11:55 AM

EBITDA grew 48% YoY at ₹210 crore, from ₹142 crore in the same quarter last year, marking better profitability.

Read More
Strides Pharma Posts ₹93 Crore Q2 Profit
28 Oct 2024|05:13 PM

EBITDA rose significantly to ₹235.7 Crore, a 54% increase from ₹153 Crore in the corresponding period of the previous year.

Read More
Strides Pharma gets shareholders’ approval for CDMO unit
11 Sep 2024|03:17 PM

In September 2023, the pharmaceutical behemoth revealed OneSource. The stock exchanges approved the idea earlier this year, in May.

Read More
Strides gets US FDA nod for Theophylline tablets
6 Sep 2024|12:18 PM

The medication is bioequivalent and therapeutically equivalent to Schering Corp's Reference Listed Drug (RLD), THEO-DUR.

Read More
Strides Pharma's Chennai Facility Receives USFDA Approval
19 Aug 2024|03:21 PM

The Alathur facility is key to Strides' global operations, especially in the US and other regulated markets, specializing in the production of tablets and capsules.

Read More
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.